pixs4u/Shutterstock.com

U.S. to push for new anthrax vaccine by 2017

The federal government has sought for years to develop a successor to BioThrax.

The United States wants to have a new anthrax vaccine ready for large-scale acquisition no later than the 2017 budget year, the Health and Human Services Department said on Monday in its implementation plan for a national health preparedness initiative.

Such a treatment could win government authorization for potential distribution during a crisis, but full licensure could take longer, Biomedical Advanced Research and Development Authority head Robin Robinson told Global Security Newswire. "We have four candidates that are in development right now, and the trajectory for being able to purchase those" would fall between 2014 and 2018, Robinson said, adding that two other possible vaccines are "under consideration."

The federal government has sought for years to develop a successor to BioThrax, the only anthrax vaccine licensed by the Food and Drug Administration. A new version of the vaccine -- which could be ready as soon as fiscal 2015 for inclusion in the Strategic National Stockpile of medical countermeasures -- might be suited for storage at room temperature for up to a decade, Robinson said. He added it could be capable of conferring immunity with fewer doses than the five required by the existing vaccine.

Efforts to facilitate development of a new anthrax vaccine have absorbed hundreds of millions of dollars to date. In one high-profile setback, Health and Human Services in 2006 canceled plans for preparation of a new anthrax vaccine by the biotechnology firm VaxGen. The current vaccine's shortcomings could complicate any emergency distribution, and they necessitate the costly replacement of stockpiled materials on an ongoing basis.

"It's an expensive undertaking but it's also risky, which is why we have a number of different candidates," Robinson said. The four developmental candidates have made varying degrees of progress toward animal and human testing.

Meanwhile, separate research activities would seek to augment the existing anthrax vaccine "through the development and testing of adjuvants that could enhance performance and reduce the doses necessary to achieve full immunity," says the plan for activities under the HHS Public Health Emergency Medical Countermeasures Enterprise. Certain augmenting agents under development promise to render the vaccine effective following exposure to the bacteria; the existing shot must be administered well in advance.

Anthrax has been identified as a leading bioterror threat. Five people died after exposure to spores dispersed through the U.S. postal system in 2001.

Robinson said "considerable progress has already been made" in pursuing goals outlined in the broader HHS implementation blueprint, which establishes time lines for completing medical preparations against a wide array of unconventional-weapon and natural disease threats. The paper calls for federal agencies to collaborate in prioritizing the development and acquisition of various medical countermeasures, refining rules for their use, establishing distribution plans and making arrangements for potential administration to minors and other "special populations."

"The next four years should be bountiful in the amount of preparedness afforded by this plan," the BARDA chief said.

The National Institutes of Health is set through fiscal 2017 to fund development of medical treatments for nerve agents and other chemical warfare materials, as well as hazardous substances from manufacturing processes. One developmental drug could aid in mitigating seizures produced by nerve agents, and officials hope to create a more potent, easier-to-administer countermeasure for cyanide.

National Institutes' personnel have identified nearly 100 potential treatments for various types ofacute radiation syndrome and related ailments, and the government intends through fiscal 2014 to select promising candidates to receive BARDA funding.

No steps to develop nonmilitary vaccines for biological "material threats" other than anthrax and smallpox are included in the HHS document, which elaborates on development priorities established in a strategy document issued earlier this year. Both papers are slated for reassessment and revision at least every half-decade.

Health and Human Services development activities would receive support from several recently established scientific organizations comprised of experts from the academic and commercial biotechnology sectors, the new emergency preparedness document notes.

(Image via pixs4u/Shutterstock.com)

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.